These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 20818581)

  • 1. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors.
    Saxena S; Chaudhaery SS; Varshney K; Saxena AK
    SAR QSAR Environ Res; 2010 Jul; 21(5-6):445-62. PubMed ID: 20818581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
    Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW
    Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular modelling and docking studies on heat shock protein 90 (Hsp90) inhibitors.
    Saxena AK; Saxena S; Chaudhaery SS
    SAR QSAR Environ Res; 2010 Jan; 21(1):1-20. PubMed ID: 20373211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.
    Aparoy P; Kumar Reddy K; Kalangi SK; Chandramohan Reddy T; Reddanna P
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1013-8. PubMed ID: 20045317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors.
    Wang HY; Cao ZX; Li LL; Jiang PD; Zhao YL; Luo SD; Yang L; Wei YQ; Yang SY
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4972-7. PubMed ID: 18762425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it.
    Wang HY; Li LL; Cao ZX; Luo SD; Wei YQ; Yang SY
    Chem Biol Drug Des; 2009 Jan; 73(1):115-26. PubMed ID: 19152640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacophore modelling, molecular docking and virtual screening for EGFR (HER 1) tyrosine kinase inhibitors.
    Gupta AK; Bhunia SS; Balaramnavar VM; Saxena AK
    SAR QSAR Environ Res; 2011 Jun; 22(3):239-63. PubMed ID: 21400356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined pharmacophore and structure-guided studies to identify diverse HSP90 inhibitors.
    Sanam R; Tajne S; Gundla R; Vadivelan S; Machiraju PK; Dayam R; Narasu L; Jagarlapudi S; Neamati N
    J Mol Graph Model; 2010 Feb; 28(6):472-7. PubMed ID: 20005756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacophore mapping of diverse classes of farnesyltransferase inhibitors.
    Equbal T; Silakari O; Rambabu G; Ravikumar M
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1594-600. PubMed ID: 17236767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore identification, docking and "in silico" screening for novel CDK1 inhibitors.
    Dong X; Yan J; Du L; Wu P; Huang S; Liu T; Hu Y
    J Mol Graph Model; 2012 Jul; 37():77-86. PubMed ID: 22622012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacophore modelling and virtual screening for identification of new Aurora-A kinase inhibitors.
    Deng XQ; Wang HY; Zhao YL; Xiang ML; Jiang PD; Cao ZX; Zheng YZ; Luo SD; Yu LT; Wei YQ; Yang SY
    Chem Biol Drug Des; 2008 Jun; 71(6):533-9. PubMed ID: 18410307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment.
    Chen Y; Li H; Tang W; Zhu C; Jiang Y; Zou J; Yu Q; You Q
    Eur J Med Chem; 2009 Jul; 44(7):2868-76. PubMed ID: 19136179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
    Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
    J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure based design of heat shock protein 90 inhibitors acting as anticancer agents.
    Doddareddy MR; Thorat DA; Seo SH; Hong TJ; Cho YS; Hahn JS; Pae AN
    Bioorg Med Chem; 2011 Mar; 19(5):1714-20. PubMed ID: 21306907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration-mediated prediction enrichment of quantitative model for Hsp90 inhibitors as anti-cancer agents: 3D-QSAR study.
    Roy KK; Singh S; Saxena AK
    Mol Divers; 2011 May; 15(2):477-89. PubMed ID: 20740314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into designing the dual-targeted HER2/HSP90 inhibitors.
    Chen CY; Chen CY
    J Mol Graph Model; 2010 Aug; 29(1):21-31. PubMed ID: 20471294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of potential HIV-1 integrase strand transfer inhibitors: in silico virtual screening and QM/MM docking studies.
    Reddy KK; Singh SK; Tripathi SK; Selvaraj C
    SAR QSAR Environ Res; 2013; 24(7):581-95. PubMed ID: 23521430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
    Islam MA; Pillay TS
    J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophore based virtual screening, molecular docking studies to design potent heat shock protein 90 inhibitors.
    Sakkiah S; Thangapandian S; John S; Lee KW
    Eur J Med Chem; 2011 Jul; 46(7):2937-47. PubMed ID: 21531051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of potent virtual leads to design novel indoleamine 2,3-dioxygenase inhibitors: pharmacophore modeling and molecular docking studies.
    John S; Thangapandian S; Sakkiah S; Lee KW
    Eur J Med Chem; 2010 Sep; 45(9):4004-12. PubMed ID: 20580138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.